{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:58:19Z","timestamp":1758272299576},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Cardiovascular (CV) complications are the most frequent cause of morbidity\nand mortality in autosomal dominant polycystic kidney disease (ADPKD) patients. In 2017, the\nItalian Medicines Agency authorised tolvaptan, a vasopressin V2 receptor antagonist, for the treatment\nof ADPKD, based on the Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO\n3: 4), TEMPO 4: 4 and Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan\nSafety and Efficacy (REPRISE) studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim of the Study:<\/jats:title>\n<jats:p>The aim of the study was to assess the impact of tolvaptan on CV risk and quality\nof life, evaluated by nutritional, inflammatory, metabolic, instrumental parameters and psychocognitive\ntests on ADPKD patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and Materials:<\/jats:title>\n<jats:p>We evaluated 36 patients with ADPKD; 10 patients (7 males, mean age\n42.5\u00b17.0 years) treated with tolvaptan and 26 controls (11 males, mean age 36.7\u00b19.1 years). They\nunderwent, at T0, monthly, and at T1 (1 year) clinical, laboratory and instrumental evaluation, in\naddition to psychocognitive tests.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In ADPKD patients treated with tolvaptan, we found at T1, a decrease in carotid intima--\nmedia thickness (p=0.048), epicardial adipose tissue thickness (p=0.002), C-reactive protein\n(p=0.026), sympathovagal balance during night (p=0.045) and increased flow-mediated dilation\n(p=0.023) with a reduction in depression (Hamilton and Beck tests, p=0.008 and p=0.002, respectively)\ncompared with controls.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>These preliminary results suggest that treatment with tolvaptan could improve early\natherosclerosis and endothelial dysfunction markers and improve mood in ADPKD patients (probably\nby acting on endothelial cell and adipocyte V2 receptors).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161118999200918094809","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T04:22:07Z","timestamp":1600662127000},"page":"556-564","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study"],"prefix":"10.2174","volume":"19","author":[{"given":"Silvia","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mangiulli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo M.","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Gigante","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Napoleoni","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cipolloni","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna P.","family":"Mitterhofer","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Gasperini","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Muscaritoli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Cianci","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Giovannetti","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Falco","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mastroluca","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"Chebib F.T.","year":"2016","unstructured":"Chebib F.T.; Torres V.E.; Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis 2016,67(5),792-810","journal-title":"Am J Kidney Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1523-1755.2005.00201.x","volume":"67","author":"Ong A.C.","year":"2005","unstructured":"Ong A.C.; Harris P.C.; Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005,67(4),1234-1247","journal-title":"Kidney Int"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"Porath B.","year":"2016","unstructured":"Porath B.; Gainullin V.G.; Cornec-Le Gall E.; Dillinger E.K.; Heyer C.M.; Hopp K.; Edwards M.E.; Madsen C.D.; Mauritz S.R.; Banks C.J.; Baheti S.; Reddy B.; Herrero J.I.; Ba\u00f1ales J.M.; Hogan M.C.; Tasic V.; Watnick T.J.; Chapman A.B.; Vigneau C.; Lavainne F.; Audr\u00e9zet M.P.; Ferec C.; Le Meur Y.; Torres V.E.; Harris P.C.; Mutations in GANAB, Encoding the Glucosidase II\u03b1 Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group2016,98(6),1193-1207","journal-title":"Am J Hum Genet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"Torres V.E.","year":"2014","unstructured":"Torres V.E.; Harris P.C.; Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014,25(1),18-32","journal-title":"J Am Soc Nephrol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573402111309010002","volume":"9","author":"Ecder T.","year":"2013","unstructured":"Ecder T.; Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 2013,9(1),2-11","journal-title":"Curr Hypertens Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1159\/000486011","volume":"42","author":"Lai S.","year":"2017","unstructured":"Lai S.; Mastroluca D.; Matino S.; Panebianco V.; Vitarelli A.; Capotosto L.; Turinese I.; Marinelli P.; Rossetti M.; Galani A.; Baiocchi P.; D\u2019Angelo A.R.; Palange P.; Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease. Kidney Blood Press Res 2017,42(6),1290-1302","journal-title":"Kidney Blood Press Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S136359","volume":"11","author":"Barnawi R.A.","year":"2018","unstructured":"Barnawi R.A.; Attar R.Z.; Alfaer S.S.; Safdar O.Y.; Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment. Int J Nephrol Renovasc Dis 2018,11,53-67","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"Torres V.E.","year":"2012","unstructured":"Torres V.E.; Chapman A.B.; Devuyst O.; Gansevoort R.T.; Grantham J.J.; Higashihara E.; Perrone R.D.; Krasa H.B.; Ouyang J.; Czerwiec F.S.; Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med TEMPO 3:4 Trial Investigators2012,367(25),2407-2418","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"Torres V.E.","year":"2017","unstructured":"Torres V.E.; Chapman A.B.; Devuyst O.; Gansevoort R.T.; Perrone R.D.; Koch G.; Ouyang J.; McQuade R.D.; Blais J.D.; Czerwiec F.S.; Sergeyeva O.; Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med REPRISE Trial Investigators2017,377(20),1930-1942","journal-title":"N Engl J Med"},{"key":"ref=10","first-page":"969","volume":"32","author":"Grantham J.J.","year":"2017","unstructured":"Grantham J.J.; Chapman A.B.; Blais J.; Czerwiec F.S.; Devuyst O.; Gansevoort R.T.; Higashihara E.; Krasa H.; Zhou W.; Ouyang J.; Perrone R.D.; Torres V.E.; Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant TEMPO 3:4 Investigators2017,32(6),969-975","journal-title":"Nephrol Dial Transplant"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"Torres V.E.","year":"2018","unstructured":"Torres V.E.; Chapman A.B.; Devuyst O.; Gansevoort R.T.; Perrone R.D.; Dandurand A.; Ouyang J.; Czerwiec F.S.; Blais J.D.; Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant TEMPO 4:4 Trial Investigators2018,33(3),477-489","journal-title":"Nephrol Dial Transplant"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"Irazabal M.V.","year":"2015","unstructured":"Irazabal M.V.; Rangel L.J.; Bergstralh E.J.; Osborn S.L.; Harmon A.J.; Sundsbak J.L.; Bae K.T.; Chapman A.B.; Grantham J.J.; Mrug M.; Hogan M.C.; El-Zoghby Z.M.; Harris P.C.; Erickson B.J.; King B.F.; Torres V.E.; Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol CRISP Investigators2015,26(1),160-172","journal-title":"J Am Soc Nephrol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"Devuyst O.","year":"2017","unstructured":"Devuyst O.; Chapman A.B.; Gansevoort R.T.; Higashihara E.; Perrone R.D.; Torres V.E.; Blais J.D.; Zhou W.; Ouyang J.; Czerwiec F.S.; Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol 2017,28(5),1592-1602","journal-title":"J Am Soc Nephrol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jamainternmed.2014.2482","volume":"174","author":"Rodriguez C.J.","year":"2014","unstructured":"Rodriguez C.J.; Swett K.; Agarwal S.K.; Folsom A.R.; Fox E.R.; Loehr L.R.; Ni H.; Rosamond W.D.; Chang P.P.; Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. JAMA Intern Med 2014,174(8),1252-1261","journal-title":"JAMA Intern Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1210\/jc.2003-030698","volume":"88","author":"Iacobellis G.","year":"2003","unstructured":"Iacobellis G.; Ribaudo M.C.; Assael F.; Vecci E.; Tiberti C.; Zappaterreno A.; Di Mario U.; Leonetti F.; Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003,88(11),5163-5168","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang R.M.","year":"2005","unstructured":"Lang R.M.; Bierig M.; Devereux R.B.; Flachskampf F.A.; Foster E.; Pellikka P.A.; Picard M.H.; Roman M.J.; Seward J.; Shanewise J.S.; Solomon S.D.; Spencer K.T.; Sutton M.S.; Stewart W.J.; Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Chamber Quantification Writing Group2005,18(12),1440-1463","journal-title":"J Am Soc Echocardiogr"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/08037051.2012.680691","volume":"21","author":"Orscelik O.","year":"2012","unstructured":"Orscelik O.; Kocyigit I.; Baran O.; Kaya C.; Dogdu O.; Zengin H.; Karadavut S.; Gedikli O.; Kut E.; Duran M.; Calapkorur B.; Tokgoz B.; Kaya M.G.; Impairment of heart rate recovery index in autosomal-dominant polycystic kidney disease patients without hypertension. Blood Press 2012,21(5),300-305","journal-title":"Blood Press"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1159\/000502419","volume":"44","author":"Lai S.","year":"2019","unstructured":"Lai S.; Mangiulli M.; Perrotta A.M.; Di Lazzaro Giraldi G.; Testorio M.; Rosato E.; Cianci R.; Gigante A.; Reduction in Heart Rate Variability in Autosomal Dominant Polycystic Kidney Disease. Kidney Blood Press Res 2019,44(5),1142-1148","journal-title":"Kidney Blood Press Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1161\/CIRCULATIONAHA.105.579268","volume":"113","author":"Ho C.Y.","year":"2006","unstructured":"Ho C.Y.; Solomon S.D.; A clinician\u2019s guide to tissue Doppler imaging. Circulation 2006,113(10),e396-e398","journal-title":"Circulation"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","volume":"39","author":"Corretti M.C.","year":"2002","unstructured":"Corretti M.C.; Anderson T.J.; Benjamin E.J.; Celermajer D.; Charbonneau F.; Creager M.A.; Deanfield J.; Drexler H.; Gerhard-Herman M.; Herrington D.; Vallance P.; Vita J.; Vogel R.; Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol International Brachial Artery Reactivity Task Force2002,39(2),257-265","journal-title":"J Am Coll Cardiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"Folstein M.F.","year":"1975","unstructured":"Folstein M.F.; Folstein S.E.; McHugh P.R.; \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975,12(3),189-198","journal-title":"J Psychiatr Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","volume":"4","author":"Lins L","year":"2016","unstructured":"Lins L; Carvalho FM; SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med 2016,4,2050312116671725","journal-title":"SAGE Open Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"Hamilton M.","year":"1967","unstructured":"Hamilton M.; Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967,6(4),278-296","journal-title":"Br J Soc Clin Psychol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0005-7967(99)00068-6","volume":"38","author":"Steer R.A.","year":"2000","unstructured":"Steer R.A.; Rissmiller D.J.; Beck A.T.; Use of the Beck Depression Inventory-II with depressed geriatric inpatients. Behav Res Ther 2000,38(3),311-318","journal-title":"Behav Res Ther"},{"key":"ref=25","first-page":"183","volume":"1","author":"Hadi H.A.","year":"2005","unstructured":"Hadi H.A.; Carr C.S.; Al Suwaidi J.; Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005,1(3),183-198","journal-title":"Vasc Health Risk Manag"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","volume":"340","author":"Celermajer D.S.","year":"1992","unstructured":"Celermajer D.S.; Sorensen K.E.; Gooch V.M.; Spiegelhalter D.J.; Miller O.I.; Sullivan I.D.; Lloyd J.K.; Deanfield J.E.; Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992,340(8828),1111-1115","journal-title":"Lancet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1046\/j.1523-1755.2003.00236.x","volume":"64","author":"Wang D.","year":"2003","unstructured":"Wang D.; Iversen J.; Wilcox C.S.; Strandgaard S.; Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003,64(4),1381-1388","journal-title":"Kidney Int"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/j.ajkd.2004.01.011","volume":"43","author":"Kocaman O.","year":"2004","unstructured":"Kocaman O.; Oflaz H.; Yekeler E.; Dursun M.; Erdogan D.; Demirel S.; Alisir S.; Turgut F.; Mercanoglu F.; Ecder T.; Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004,43(5),854-860","journal-title":"Am J Kidney Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1046\/j.1523-1755.2003.00913.x","volume":"63","author":"Al-Nimri M.A.","year":"2003","unstructured":"Al-Nimri M.A.; Komers R.; Oyama T.T.; Subramanya A.R.; Lindsley J.N.; Anderson S.; Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003,63(5),1776-1784","journal-title":"Kidney Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"18L","DOI":"10.1016\/S0002-9149(02)02957-0","volume":"90","author":"O\u2019Leary D.H.","year":"2002","unstructured":"O\u2019Leary D.H.; Polak J.F.; Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002,90(10C),18L-21L","journal-title":"Am J Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.echo.2009.10.013","volume":"22","author":"Iacobellis G.","year":"2009","unstructured":"Iacobellis G.; Willens H.J.; Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009,22(12),1311-1319","journal-title":"J Am Soc Echocardiogr"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40064-016-1871-8","volume":"5","author":"Sag S.","year":"2016","unstructured":"Sag S.; Yildiz A.; Gullulu S.; Gungoren F.; Ozdemir B.; Cegilli E.; Oruc A.; Ersoy A.; Gullulu M.; Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness. Springerplus 2016,5,211","journal-title":"Springerplus"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000488064","volume":"8","author":"Concistr\u00e8 A.","year":"2018","unstructured":"Concistr\u00e8 A.; Petramala L.; Scoccia G.; Sciomer S.; Bisogni V.; Saracino V.; Iannucci G.; Lai S.; Mastroluca D.; Iacobellis G.; Letizia C.; Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease. Cardiorenal Med 2018,8(3),199-207","journal-title":"Cardiorenal Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"Gheorghiade M.","year":"2003","unstructured":"Gheorghiade M.; Niazi I.; Ouyang J.; Czerwiec F.; Kambayashi J.; Zampino M.; Orlandi C.; Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation Tolvaptan Investigators2003,107(21),2690-2696","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1071-9164(03)00234-3","volume":"9","author":"Burnett J.C.","year":"2003","unstructured":"Burnett J.C.; Smith W.B.; Ouyang J.; Zimmer C.A.; Orlandi C.; Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J Card Fail 2003,9,36","journal-title":"J Card Fail"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"Udelson J.E.","year":"2007","unstructured":"Udelson J.E.; McGrew F.A.; Flores E.; Ibrahim H.; Katz S.; Koshkarian G.; O\u2019Brien T.; Kronenberg M.W.; Zimmer C.; Orlandi C.; Konstam M.A.; Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007,49(22),2151-2159","journal-title":"J Am Coll Cardiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1538-7836.2003.00197.x","volume":"1","author":"Kaufmann J.E.","year":"2003","unstructured":"Kaufmann J.E.; Iezzi M.; Vischer U.M.; Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003,1(4),821-828","journal-title":"J Thromb Haemost"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","volume":"1","author":"Kaufmann J.E.","year":"2003","unstructured":"Kaufmann J.E.; Vischer U.M.; Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003,1(4),682-689","journal-title":"J Thromb Haemost"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","volume":"4","author":"Vischer U.M.","year":"2006","unstructured":"Vischer U.M.; von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006,4(6),1186-1193","journal-title":"J Thromb Haemost"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1084\/jem.20012044","volume":"196","author":"Massberg S.","year":"2002","unstructured":"Massberg S.; Brand K.; Gr\u00fcner S.; Page S.; M\u00fcller E.; M\u00fcller I.; Bergmeier W.; Richter T.; Lorenz M.; Konrad I.; Nieswandt B.; Gawaz M.; A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002,196(7),887-896","journal-title":"J Exp Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood.V99.12.4486","volume":"99","author":"Theilmeier G.","year":"2002","unstructured":"Theilmeier G.; Michiels C.; Spaepen E.; Vreys I.; Collen D.; Vermylen J.; Hoylaerts M.F.; Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002,99(12),4486-4493","journal-title":"Blood"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.V98.5.1424","volume":"98","author":"Methia N.","year":"2001","unstructured":"Methia N.; Andr\u00e9 P.; Denis C.V.; Economopoulos M.; Wagner D.D.; Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001,98(5),1424-1428","journal-title":"Blood"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s10157-018-1542-x","volume":"22","author":"Lee Y.","year":"2018","unstructured":"Lee Y.; Blount K.L.; Dai F.; Thompson S.; Scher J.K.; Bitterman S.; Droher M.; Herzog E.L.; Moeckel G.; Karihaloo A.; Dahl N.K.; Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment. Clin Exp Nephrol 2018,22(4),906-916","journal-title":"Clin Exp Nephrol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"Uhlen M.","year":"2010","unstructured":"Uhlen M.; Oksvold P.; Fagerberg L.; Lundberg E.; Jonasson K.; Forsberg M.; Zwahlen M.; Kampf C.; Wester K.; Hober S.; Wernerus H.; Bj\u00f6rling L.; Ponten F.; Towards a knowledge-based human protein atlas. Nat Biotechnol 2010,28(12),1248-1250","journal-title":"Nat Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1253\/circj.CJ-15-0588","volume":"80","author":"Li H.R.","year":"2016","unstructured":"Li H.R.; Lu T.M.; Cheng H.M.; Lu D.Y.; Chiou C.W.; Chuang S.Y.; Yang A.C.; Sung S.H.; Yu W.C.; Chen C.H.; Additive Value of Heart Rate Variability in Predicting Obstructive Coronary Artery Disease Beyond Framingham Risk. Circ J 2016,80(2),494-501","journal-title":"Circ J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00005344-199004000-00009","volume":"15","author":"Ko\u017aniewska E.","year":"1990","unstructured":"Ko\u017aniewska E.; Szczepa\u0144ska-Sadowska E.; V2-like receptors mediate cerebral blood flow increase following vasopressin administration in rats. J Cardiovasc Pharmacol 1990,15(4),579-585","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","volume":"306","author":"Juul K.V.","year":"2014","unstructured":"Juul K.V.; Bichet D.G.; Nielsen S.; N\u00f8rgaard J.P.; The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol 2014,306(9),F931-F940","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186036\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:28:16Z","timestamp":1643779696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186036\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161118999200918094809","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}